How Analysts Feel About SCYNEXIS, Inc. (NASDAQ:SCYX)?

December 20, 2017 - By Hazel Jackson

 How Analysts Feel About SCYNEXIS, Inc. (NASDAQ:SCYX)?
Investors sentiment decreased to 1 in 2017 Q2. Its down 0.80, from 1.8 in 2017Q1. It dived, as 8 investors sold SCYNEXIS, Inc. shares while 7 reduced holdings. 7 funds opened positions while 8 raised stakes. 9.22 million shares or 20.12% less from 11.54 million shares in 2017Q1 were reported.
Granite Point Cap Management Ltd Partnership holds 0.06% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX) for 141,750 shares. Dafna Ltd Company invested 0.65% in SCYNEXIS, Inc. (NASDAQ:SCYX). Vanguard Grp Inc Inc stated it has 0% in SCYNEXIS, Inc. (NASDAQ:SCYX). Gsa Capital Prtn Llp invested in 176,700 shares or 0.02% of the stock. Retail Bank Of Mellon owns 24,945 shares. Tower Research Cap Ltd Co (Trc) invested in 1,729 shares or 0% of the stock. Private Advisor Group Limited Liability invested 0.01% in SCYNEXIS, Inc. (NASDAQ:SCYX). Asset has 0.1% invested in SCYNEXIS, Inc. (NASDAQ:SCYX) for 307,630 shares. Northern Trust Corp holds 0% or 41,692 shares in its portfolio. 11,100 were reported by Rbf Cap Limited Liability Corporation. Blackrock Inc invested in 0% or 98,796 shares. Morgan Stanley owns 15 shares for 0% of their portfolio. Bridgeway Cap Management Incorporated reported 50,000 shares. Susquehanna International Limited Liability Partnership stated it has 12,858 shares. California Public Employees Retirement Systems invested in 200,000 shares.

SCYNEXIS, Inc. (NASDAQ:SCYX) Ratings Coverage

Among 7 analysts covering Scynexis Inc (NASDAQ:SCYX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Scynexis Inc had 13 analyst reports since August 20, 2015 according to SRatingsIntel. The stock has “Outperform” rating by RBC Capital Markets on Monday, November 16. The stock of SCYNEXIS, Inc. (NASDAQ:SCYX) earned “Buy” rating by H.C. Wainwright on Thursday, October 20. Roth Capital maintained the stock with “Buy” rating in Monday, August 7 report. The firm earned “Buy” rating on Wednesday, August 17 by Guggenheim. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 16. Brean Capital initiated the shares of SCYX in report on Monday, March 28 with “Buy” rating. The stock has “Hold” rating by Needham on Wednesday, August 9. WBB Securities upgraded the shares of SCYX in report on Tuesday, August 9 to “Buy” rating. Brean Capital initiated SCYNEXIS, Inc. (NASDAQ:SCYX) on Monday, October 3 with “Buy” rating. The firm has “Strong Buy” rating given on Tuesday, December 29 by WBB Securities. Below is a list of SCYNEXIS, Inc. (NASDAQ:SCYX) latest ratings and price target changes.

24/10/2017 Broker: Guggenheim Rating: Buy New Target: $6 Initiates Coverage On
16/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $14.0 Maintain
09/08/2017 Broker: Needham Rating: Hold Maintain
07/08/2017 Broker: Roth Capital Rating: Buy New Target: $8.5000 Maintain

The stock decreased 3.02% or $0.07 during the last trading session, reaching $2.25. About 156,443 shares traded. SCYNEXIS, Inc. (NASDAQ:SCYX) has declined 46.67% since December 20, 2016 and is downtrending. It has underperformed by 63.37% the S&P500.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The company has market cap of $64.26 million. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. It currently has negative earnings. The firm also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis.

More notable recent SCYNEXIS, Inc. (NASDAQ:SCYX) news were published by: Seekingalpha.com which released: “Scynexis: A $2 ‘Busted IPO’ And Lottery Ticket?” on September 18, 2017, also Seekingalpha.com with their article: “Scynexis: Another Buy Opportunity On The Recent Pullback” published on May 15, 2017, Globenewswire.com published: “SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on …” on May 08, 2017. More interesting news about SCYNEXIS, Inc. (NASDAQ:SCYX) were released by: Globenewswire.com and their article: “SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017” published on September 27, 2017 as well as Seekingalpha.com‘s news article titled: “Scynexis: This Cash-Rich $2 Biotech Stock Is A Strong Buy Before 2018” with publication date: December 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.